SCHEMBL17411

SCHEMBL17411

CCCCOC[C@@H]1NC(=O)CNC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.41
CRBN Q96SW2 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
NOS1 P29475 1/20 0.38
NPC1 O15118 1/20 0.35
POLB P06746 2/20 0.35
KMT2A Q03164 1/20 0.35
MAOA P21397 1/20 0.35
MAOB P27338 1/20 0.35
LMNA P02545 1/20 0.35
NAAA Q02083 2/20 0.34
ALDH1A1 P00352 2/20 0.33
TDP1 Q9NUW8 1/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ITGB3 P05106 2/20 0.32
ITGA2B P08514 1/20 0.32
DDB1 Q16531 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4838753 0.83 HRH3 (0.36) HRH3NOS1ITGB3ITGA2B
SCHEMBL14156666 0.83 HRH3 (0.36) HRH3NOS1ITGB3ITGA2B
SCHEMBL4838771 0.83 HRH3 (0.36) HRH3NOS1ITGB3ITGA2B
SCHEMBL2418713 0.78 ITGB3 (0.42) KMT2AALDH1A1ITGB3ITGA2BITGAV
SCHEMBL31509536 0.78 ITGB3 (0.42) KMT2AALDH1A1ITGB3ITGA2BITGAV
SCHEMBL4839050 0.76 HRH3 (0.37) HRH3ITGB3ITGAV
SCHEMBL14156697 0.76 HRH3 (0.37) HRH3ITGB3ITGAV
SCHEMBL4839044 0.76 HRH3 (0.37) HRH3ITGB3ITGAV
SCHEMBL27637759 0.76 LMNA (0.47) CRBNSMN1; SMN2NOS1NPC1POLB
SCHEMBL31509521 0.74 GHSR (0.41) HRH3ITGB3ITGA2BITGAVITGB5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2013123444-A1 SULFONYL COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN AMGEN INC. (US) 2013-08-22 WO disclosed
US-8431563-B2 Compounds that interact with glucokinase regulatory protein for the treatment of diabetes AMGEN INC. (US) 2013-04-30 US disclosed
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-09-06 US disclosed
WO-2012027261-A1 SULFONYLPIPERAZINE DERIVATIVES THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES AMGEN INC. (US) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225854-A1 COMPOUNDS THAT INTERACT WITH GLUCOKINASE REGULATORY PROTEIN FOR THE TREATMENT OF DIABETES GCKR, GCK, SLC5A2 HRH3 4864/4885CRBN 2728/4885SMN1; SMN2 4413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.